Mindfulness and its efficacy for psychological and biological responses in women with breast cancer

Cancer Medicine

Volumn 6, Issue 5, 2017, Pages 1108-1122

  Kenne Sarenmalm, Elisabeth ^a   Mårtensson, Lena B ^b   Andersson, Bengt A ^c   Karlsson, Per ^c   Bergh, Ingrid ^b  

^a SKARABORG HOSPITAL   (Sweden)

^b UNIVERSITY OF SKÖVDE   (Sweden)

^c SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Breast cancer; immune response; mindfulness based stress reduction; randomized clinical trial

Indexed keywords

INTERLEUKIN 6; INTERLEUKIN 8; IL6 PROTEIN, HUMAN; IL8 PROTEIN, HUMAN;

ARTICLE; BREAST CANCER; CELL ACTIVITY; CELL COUNT; CLINICAL EFFECTIVENESS; COPING BEHAVIOR; DEPRESSION; DISTRESS SYNDROME; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FIVE FACETS OF MINDFULNESS QUESTIONNAIRE; HEALTH STATUS; HOSPITAL ANXIETY AND DEPRESSION SCALE; HUMAN; LYMPHOCYTE; MAJOR CLINICAL STUDY; MEMORIAL SYMPTOM ASSESSMENT SCALE; MINDFULNESS; MOOD DISORDER; NATURAL KILLER CELL; PHENOTYPE; POSTTRAUMATIC GROWTH INDEX; PRIORITY JOURNAL; PSYCHOLOGIC ASSESSMENT; QUESTIONNAIRE; RATING SCALE; SCORING SYSTEM; SENSE OF COHERENCE SCALE; SHORT FORM 36; TREATMENT OUTCOME; TREATMENT RESPONSE; BREAST TUMOR; CANCER SURVIVOR; CONTROLLED STUDY; IMMUNOLOGY; LONGITUDINAL STUDY; METABOLISM; PROCEDURES; PSYCHOLOGY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL;

ADAPTATION, PSYCHOLOGICAL; BREAST NEOPLASMS; CANCER SURVIVORS; FEMALE; HUMANS; INTERLEUKIN-6; INTERLEUKIN-8; KILLER CELLS, NATURAL; LONGITUDINAL STUDIES; MINDFULNESS; QUALITY OF LIFE; SURVEYS AND QUESTIONNAIRES; TREATMENT OUTCOME;

EID: 85018595351     PISSN: None     EISSN: 20457634     Source Type: Journal    
DOI: 10.1002/cam4.1052     Document Type: Article

References (73)

1. Fallowfield, L., and V. Jenkins. 2015. Psychosocial/survivorship issues in breast cancer: are we doing better? J. Natl Cancer Inst. 107:335.
2. Given, C. W., A. Sikorskii, D. Tamkus, B. Given, M. You, R. McCorkle, et al. 2008. Managing symptoms among patients with breast cancer during chemotherapy: results of a two-arm behavioral trial. J. Clin. Oncol. 26:5855–5862.
3. Kenne Sarenmalm, E., M. Browall, and F. Gaston-Johansson. 2014. Symptom burden clusters: a challenge for targeted symptom management. A longitudinal study examining symptom burden clusters in breast cancer. J. Pain Symptom Manage. 47:731–741.
4. Hjerl, K., E. W. Andersen, N. Keiding, P. B. Mortensen, and T. Jorgensen 2002. Increased incidence of affective disorders, anxiety disorders, and non-natural mortality in women after breast cancer diagnosis: a nation-wide cohort study in Denmark. Acta Psychiatr. Scand. 105:258–264.
5. Zabora, J., K. BrintzenhofeSzoc, B. Curbow, C. Hooker, and S. Piantadosi 2001. The prevalence of psychological distress by cancer site. Psychooncology 10:19–28.
6. Mehnert, A., and U. Koch. 2007. Prevalence of acute and post-traumatic stress disorder and comorbid mental disorders in breast cancer patients during primary cancer care: a prospective study. Psychooncology 16:181–188.
7. Mehnert, A., and U. Koch. 2008. Psychological comorbidity and health-related quality of life and its association with awareness, utilization, and need for psychosocial support in a cancer register-based sample of long-term breast cancer survivors. J. Psychosom. Res. 64:383–391.
8. Burgess, C., V. Cornelius, S. Love, J. Graham, M. Richards, and A. Ramirez. 2005. Depression and anxiety in women with early breast cancer: five year observational cohort study. BMJ 330:702.
9. Berger, A. M., C. Visovsky, M. Hertzog, S. Holtz, and F. R. Loberiza Jr, 2012. Usual and worst symptom severity and interference with function in breast cancer survivors. J. Support. Oncol. 10:112–118.
10. Segerstrom, S. C., and G. E. Miller. 2004. Psychological stress and the human immune system: a meta-analytic study of 30 years of inquiry. Psychol. Bull. 130:601–630.
11. Thornton, L. M., B. L. Andersen, T. R. Crespin, and W. E. Carson 2007. Individual trajectories in stress covary with immunity during recovery from cancer diagnosis and treatments. Brain Behav. Immun. 21:185–194.
12. Andersen, B. L., W. B. Farrar, D. Golden-Kreutz, L. A. Kutz, R. MacCallum, M. E. Courtney, et al. 1998. Stress and immune responses after surgical treatment for regional breast cancer. J. Natl Cancer Inst. 90:30–36.
13. Wiltschke, C., M. Krainer, A. C. Budinsky, A. Berger, C. Muller, R. Zeillinger, et al. 1995. Reduced mitogenic stimulation of peripheral blood mononuclear cells as a prognostic parameter for the course of breast cancer: a prospective longitudinal study. Br. J. Cancer 71:1292–1296.
14. Yamasaki, S., N. Kan, T. Harada, Y. Ichinose, Y. Moriguchi, L. Li, et al. 1993. Relationship between immunological parameters and survival of patients with liver metastases from breast cancer given immuno-chemotherapy. Breast Cancer Res. Treat. 26:55–65.
15. Standish, L. J., E. S. Sweet, J. Novack, C. A. Wenner, C. Bridge, A. Nelson, et al. 2008. Breast cancer and the immune system. J. Soc. Integr. Oncol. 6:158–168.
16. Rao, V. S., C. E. Dyer, J. K. Jameel, P. J. Drew, and J. Greenman, 2006. Potential prognostic and therapeutic roles for cytokines in breast cancer (Review). Oncol. Rep. 15:179–185.
17. Yokoe, T., Y. Iino, and Y. Morishita. 2000. Trends of IL-6 and IL-8 levels in patients with recurrent breast cancer: preliminary report. Breast Cancer 7:187–190.
18. Bachelot, T., I. Ray-Coquard, C. Menetrier-Caux, M. Rastkha, A. Duc, and J. Y. Blay 2003. Prognostic value of serum levels of interleukin 6 and of serum and plasma levels of vascular endothelial growth factor in hormone-refractory metastatic breast cancer patients. Br. J. Cancer 88:1721–1726.
19. Salgado, R., S. Junius, I. Benoy, P. Van Dam, P. Vermeulen, E. Van Marck, et al. 2003. Circulating interleukin-6 predicts survival in patients with metastatic breast cancer. Int. J. Cancer 103:642–646.
20. Kabat-Zinn, J., A. O. Massion, J. Kristeller, L. G. Peterson, K. E. Fletcher, L. Pbert, et al. 1992. Effectiveness of a meditation-based stress reduction program in the treatment of anxiety disorders. Am. J. Psychiatry 149:936–943.
21. Hoffman, C. J., S. J. Ersser, J. B. Hopkinson, P. G. Nicholls, J. E. Harrington, P. W. Thomas. 2012. Effectiveness of mindfulness-based stress reduction in mood, breast- and endocrine-related quality of life, and well-being in stage 0 to III breast cancer: a randomized, controlled trial. J. Clin. Oncol. 30:1335–1342.
22. Gotink, R. A., P. Chu, J. J. Busschbach, H. Benson, G. L. Fricchione, and M. G. Hunink 2015. Standardised mindfulness-based interventions in healthcare: an overview of systematic reviews and meta-analyses of RCTs. PLoS ONE 10:e0124344.
23. Piet, J., H. Wurtzen, and R. Zachariae. 2012. The effect of mindfulness-based therapy on symptoms of anxiety and depression in adult cancer patients and survivors: a systematic review and meta-analysis. J. Consult. Clin. Psychol. 80:1007–1020.
24. Kabat-Zinn, J. 1994. Wherever you go, there you are: Mindfulness meditation for everyday life. Piatkus, London.
25. Marcus, M. T., P. R. Liehr, J. Schmitz, F. G. Moeller, P. Swank, M. Fine, et al. 2007. Behavioral therapies trials: a case example. Nurs. Res. 56:210–216.
26. Wurtzen, H., S. O. Dalton, P. Elsass, A. D. Sumbundu, M. Steding-Jensen, R. V. Karlsen, et al. 2013. Mindfulness significantly reduces self-reported levels of anxiety and depression: results of a randomised controlled trial among 336 Danish women treated for stage I-III breast cancer. Eur. J. Cancer 49:1365–1373.
27. Speca, M., L. E. Carlson, E. Goodey, and M. Angen. 2000. A randomized, wait-list controlled clinical trial: the effect of a mindfulness meditation-based stress reduction program on mood and symptoms of stress in cancer outpatients. Psychosom. Med. 62:613–622.
28. Branstrom, R., P. Kvillemo, Y. Brandberg, and J. T. Moskowitz. 2010. Self-report mindfulness as a mediator of psychological well-being in a stress reduction intervention for cancer patients–a randomized study. Ann. Behav. Med. 39:151–161.
29. Lengacher, C. A., M. M. Shelton, R. R. Reich, M. K. Barta, V. Johnson-Mallard, M. S. Moscoso, et al. 2014. Mindfulness based stress reduction (MBSR(BC)) in breast cancer: evaluating fear of recurrence (FOR) as a mediator of psychological and physical symptoms in a randomized control trial (RCT). J. Behav. Med. 37:185–195.
30. Branstrom, R., P. Kvillemo, and T. Akerstedt. 2013. Effects of mindfulness training on levels of cortisol in cancer patients. Psychosomatics 54:158–164.
31. Carlson, L. E., M. Speca, P. Faris, and K. D. Patel. 2007. One year pre-post intervention follow-up of psychological, immune, endocrine and blood pressure outcomes of mindfulness-based stress reduction (MBSR) in breast and prostate cancer outpatients. Brain Behav. Immun. 21:1038–1049.
32. Witek-Janusek, L., K. Albuquerque, K. R. Chroniak, R. Durazo-Arvizu, and H. L. Mathews. 2008. Effect of mindfulness based stress reduction on immune function, quality of life and coping in women newly diagnosed with early stage breast cancer. Brain Behav. Immun. 22:969–981.
33. Carlson, L. E., M. Speca, K. D. Patel, and E. Goodey 2003. Mindfulness-based stress reduction in relation to quality of life, mood, symptoms of stress, and immune parameters in breast and prostate cancer outpatients. Psychosom. Med. 65:571–581.
34. Rouleau, C. R., S. N. Garland, and L. E. Carlson. 2015. The impact of mindfulness-based interventions on symptom burden, positive psychological outcomes, and biomarkers in cancer patients. Cancer Manag. Res. 7:121–131.
35. Baer, R. A. 2003. Mindulness training as a clinical intervention: a conceptual review. Clin. Psychol. Sci. Pract. 10:125–143.
36. Grossman, P., L. Niemann, S. Schmidt, and H. Walach 2004. Mindfulness-based stress reduction and health benefits. A meta-analysis. J. Psychosom. Res. 57:35–43.
37. Kenne Sarenmalm, E., L. B. Martensson, S. B. Holmberg, B. A. Andersson, A. Oden, and I. Bergh. 2013. Mindfulness based stress reduction study design of a longitudinal randomized controlled complementary intervention in women with breast cancer. BMC Complement Altern. Med. 13:248.
38. Altman, D. G., K. F. Schulz, D. Moher, M. Egger, F. Davidoff, D. Elbourne, et al. 2001. The revised CONSORT statement for reporting randomized trials: explanation and elaboration. Ann. Intern. Med. 134:663–694.
39. Zwarenstein, M., S. Treweek, J. J. Gagnier, D. G. Altman, S. Tunis, B. Haynes, et al. 2008. Improving the reporting of pragmatic trials: an extension of the CONSORT statement. BMJ 337:a2390.
40. Boutron, I., D. Moher, D. G. Altman, K. F. Schulz, P. Ravaud and C. Group. 2008. Methods and processes of the CONSORT Group: example of an extension for trials assessing nonpharmacologic treatments. Ann. Intern. Med. 148:W60–W66.
41. Power, M., and K. Hopayian. 2011. Exposing the evidence gap for complementary and alternative medicine to be integrated into science-based medicine. J. R. Soc. Med. 104:155–161.
42. Group TSBC: National Guidelines, 2008.
43. Zigmond, A. S., and R. P. Snaith. 1983. The hospital anxiety and depression scale. Acta Psychiatr. Scand. 67:361–370.
44. Mykletun, A., E. Stordal, and A. A. Dahl. 2001. Hospital Anxiety and Depression (HAD) scale: factor structure, item analyses and internal consistency in a large population. Br. J. Psychiatry 179:540–544.
45. Herrmann, C. 1997. International experiences with the Hospital Anxiety and Depression Scale–a review of validation data and clinical results. J. Psychosom. Res. 42:17–41.
46. Bjelland, I., A. A. Dahl, T. T. Haug, and D. Neckelmann 2002. The validity of the Hospital Anxiety and Depression Scale. An updated literature review. J. Psychosom. Res. 52:69–77.
47. Portenoy, R. K., H. T. Thaler, A. B. Kornblith, J. M. Lepore, H. Friedlander-Klar, E. Kiyasu, et al. 1994. The memorial symptom assessment scale: an instrument for the evaluation of symptom prevalence, characteristics and distress. Eur. J. Cancer 30A:1326–1336.
48. Tranmer, J. E., D. Heyland, D. Dudgeon, D. Groll, M. Squires-Graham, and K. Coulson. 2003. Measuring the symptom experience of seriously ill cancer and noncancer hospitalized patients near the end of life with the memorial symptom assessment scale. J. Pain Symptom Manage. 25:420–429.
49. Browall, M., E. Kenne Sarenmalm, S. Nasic, Y. Wengstrom, and F. Gaston-Johansson. 2013. Validity and reliability of the Swedish version of the Memorial Symptom Assessment Scale (MSAS): an instrument for the evaluation of symptom prevalence, characteristics, and distress. J. Pain Symptom Manage. 46:131–141.
50. McHorney, C. A., J. E. Jr Ware, J. F. Lu, and C. D. Sherbourne. 1994. The MOS 36-item Short-Form Health Survey (SF-36): III. Tests of data quality, scaling assumptions, and reliability across diverse patient groups. Med. Care 32:40–66.
51. Sullivan, M., J. Karlsson, and J. E. Jr Ware. 1995. The swedish SF-36 health survey–I. evaluation of data quality, scaling assumptions, reliability and construct validity across general populations in Sweden. Soc. Sci. Med. 41:1349–1358.
52. Persson, L. O., J. Karlsson, C. Bengtsson, B. Steen, and M. Sullivan 1998. The Swedish SF-36 Health Survey II. Evaluation of clinical validity: results from population studies of elderly and women in Gothenborg. J. Clin. Epidemiol. 51:1095–1103.
53. Sullivan, M., and J. Karlsson. 1998. The Swedish SF-36 Health Survey III. Evaluation of criterion-based validity: results from normative population. J. Clin. Epidemiol. 51:1105–1113.
54. Antonovsky, A. 1987. Unraveling the mysteries of health: how people manage stress and stay well. Jossey-Bass, San Francisco.
55. Antonovsky, A. 1993. The structure and properties of the sense of coherence scale. Soc. Sci. Med. 36:725–733.
56. Langius, A., H. Bjorvell, and A. Antonovsky. 1992. The sense of coherence concept and its relation to personality traits in Swedish samples. Scand. J. Caring Sci. 6:165–171.
57. Gilbar, O. 1998. Coping with threat. Implications for women with a family history of breast cancer. Psychosomatics 39:329–339.
58. Thome, B., and I. R. Hallberg. 2004. Quality of life in older people with cancer – a gender perspective. Eur. J. Cancer Care (Engl) 13:454–463.
59. Baer, R. A., G. T. Smith, J. Hopkins, J. Krietemeyer, and L. Toney. 2006. Using self-report assessment methods to explore facets of mindfulness. Assessment 13:27–45.
60. Lilja, J. L., A. Frodi-Lundgren, J. J. Hanse, T. Josefsson, L. G. Lundh, C. Skold, et al. 2011. Five Facets Mindfulness Questionnaire–reliability and factor structure: a Swedish version. Cogn. Behav. Ther. 40:291–303.
61. Tedeschi, R. G., and L. G. Calhoun. 1996. The Posttraumatic Growth Inventory: measuring the positive legacy of trauma. J. Trauma. Stress 9:455–471.
62. Smith, S. G., and S. L. Cook. 2004. Are reports of posttraumatic growth positively biased? J. Trauma. Stress 17:353–358.
63. Godoy-Ramirez, K., K. Franck, and H. Gaines. 2000. A novel method for the simultaneous assessment of natural killer cell conjugate formation and cytotoxicity at the single-cell level by multi-parameter flow cytometry. J. Immunol. Methods 239:35–44.
64. Chung, H. J., C. J. Park, J. H. Lim, S. Jang, H. S. Chi, H. J. Im, et al. 2010. Establishment of a reference interval for natural killer cell activity through flow cytometry and its clinical application in the diagnosis of hemophagocytic lymphohistiocytosis. Int. J. Lab. Hematol. 32:239–247.
65. Strauss, C., K. Cavanagh, A. Oliver, and D. Pettman 2014. Mindfulness-based interventions for people diagnosed with a current episode of an anxiety or depressive disorder: a meta-analysis of randomised controlled trials. PLoS ONE 9:e96110.
66. Ledesma, D., and H. Kumano. 2009. Mindfulness-based stress reduction and cancer: a meta-analysis. Psychooncology 18:571–579.
67. Henderson, V. P., L. Clemow, A. O. Massion, T. G. Hurley, S. Druker, J. R. Hebert. 2012. The effects of mindfulness-based stress reduction on psychosocial outcomes and quality of life in early-stage breast cancer patients: a randomized trial. Breast Cancer Res. Treat. 131:99–109.
68. Kenne Sarenmalm, E., M. Browall, L. O. Persson, J. Fall-Dickson, and F. Gaston-Johansson 2013. Relationship of sense of coherence to stressful events, coping strategies, health status, and quality of life in women with breast cancer. Psychooncology 22:20–27.
69. Grossman, P. 2008. On measuring mindfulness in psychosomatic and psychological research. J. Psychosom. Res. 64:405–408.
70. Dunigan, J. T., B. I. Carr, and J. L. Steel. 2007. Posttraumatic growth, immunity and survival in patients with hepatoma. Dig. Dis. Sci. 52:2452–2459.
71. Bower, J. E., M. E. Kemeny, S. E. Taylor, and J. L. Fahey 1998. Cognitive processing, discovery of meaning, CD4 decline, and AIDS-related mortality among bereaved HIV-seropositive men. J. Consult. Clin. Psychol. 66:979–986.
72. Bower, J. E., M. E. Kemeny, S. E. Taylor, and J. L. Fahey. 2003. Finding positive meaning and its association with natural killer cell cytotoxicity among participants in a bereavement-related disclosure intervention. Ann. Behav. Med. 25:146–155.
73. Fang, C. Y., D. K. Reibel, M. L. Longacre, S. Rosenzweig, D. E. Campbell, and S. D. Douglas. 2010. Enhanced psychosocial well-being following participation in a mindfulness-based stress reduction program is associated with increased natural killer cell activity. J. Altern. Complement. Med. 16:531–538.